๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 21 Beijing 19 Shanghai 9 Changsha 8 Hefei 7
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou21 Beijing19 Shanghai9 Changsha8 Hefei7
All 60 locations
Target enrolment
to

Trials with a site in Guangzhou

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT07088263Breast Neoplasms
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Recruiting
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
NCT06319157Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
94
Guangzhou
2024-03
Recruiting
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
NCT06313463Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
375
Guangzhou
2024-03
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT06121557Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
NCT05978648Breast Neoplasms
wang shusen
Phase 2
116
Guangzhou
2023-09-20
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT05981014Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
196
Guangzhou
2023-08-01
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT05981001Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
170
Guangzhou
2023-08-01
Recruiting
Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
NCT06024187Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
566
Guangzhou
2022-11-23
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Not yet open
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer
NCT07741734Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
150
Guangzhou
2021-10-01
Active, closed
Robotic-Assisted Versus Endoscopic-Assisted Axillary Lymph Node Dissection in Breast Cancer
NCT07693361Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
127
Foshan, Guangzhou
2021-10-01
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
NCT06877416Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
Sun Yat-sen University
Observational
700
Guangzhou
2020-01-01
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

13 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 21 studies
PhaseStudiesRecruitingShare
Phase 39542.9%
Observational4119%
Not applicable229.5%
Phase 1229.5%
Phase 1/2229.5%
Phase 2219.5%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University77
Sun Yat-sen University43
Merck Sharp & Dohme LLC32
Guangzhou Women and Children's Medical Center20
AstraZeneca10
Eli Lilly and Company10
Novartis Pharmaceuticals10
wang shusen11
Zhuliling10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.